Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Wengerter

Vascular Surgery Pomona, NY Medical Doctor

NPI 1003259532 CMS profile 1393173

5A Medical Park Dr, Pomona, NY 10970

Open in the dashboard

General payments

$6,662

163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Wengerter of Pomona, NY is reported in the CMS Open Payments database as having received $6,662 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,012 24
2024 General $673 16
2023 General $948 18
2022 General $1,165 27
2021 General $795 27
2020 General $931 27
2019 General $1,139 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Wengerter
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sean Wengerter were reported at $1,012. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sean Wengerter Vascular Surgery median Middle half National median
2019 $1,139 $796 $226–$2,363 $163
2020 $931 $348 $118–$1,110 $114
2021 $795 $471 $158–$1,421 $132
2022 $1,165 $725 $222–$2,183 $149
2023 $948 $836 $257–$2,440 $160
2024 $673 $909 $252–$2,619 $164
2025 $1,012 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,364 74 payments
  2. Endologix, Inc. $1,423 12 payments
  3. Inari Medical, Inc. $659 19 payments
  4. Stryker Corporation $528 9 payments
  5. Medtronic, Inc. $285 7 payments
  6. Cardiovascular Systems Inc. $249 9 payments
  7. Cook Medical LLC $244 5 payments
  8. W. L. Gore & Associates, Inc. $164 3 payments
  9. Abbott Laboratories $153 5 payments
  10. Smith+Nephew, Inc. $124 1 payment
  11. Other $468 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,662 163 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $882 23 payments
  2. CT THROMBECTOMY SYSTEM KIT $793 19 payments
  3. General - Vascular Intervention General - Vascular Intervention_PI $698 17 payments
  4. Alto Abdominal Stent Graft System $449 3 payments
  5. Ovation $392 3 payments
  6. FLOWTRIEVER $331 6 payments
  7. AFX $269 2 payments
  8. Peripheral Orbital Atherectomy System $233 8 payments
  9. GENERAL VASCULAR INTERVENTION $232 12 payments
  10. GENERAL - VASCULAR INTERVENTION Vascular $229 7 payments
  11. Other $2,268 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

102

Median for Vascular Surgery: 122

Drug cost

$24,524

Median for Vascular Surgery: $14,135

Branded share of claims

85.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 25 $15,772
Eliquis Apixaban Brand 14 $7,950
Clopidogrel Clopidogrel Bisulfate Brand 48 $661
Cephalexin Generic 15 $141

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$420,144

Of which drugs: $451

Medicare patients

533

Average age 75

Services billed

5,917

259 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 51%
Ischemic heart disease 50%
Chronic kidney disease 45%
Heart failure 37%
Atrial fibrillation 31%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 62 4,307 $451

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record